Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D07LJH
|
||||
Former ID |
DIB018150
|
||||
Drug Name |
[125I]DOI
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [539045] | ||
Structure |
Download2D MOL |
||||
Formula |
C11H16INO2
|
||||
InChI |
InChI=1S/C11H16INO2/c1-7(13)4-8-5-11(15-3)9(12)6-10(8)14-2/h5-7H,4,13H2,1-3H3/i12-2
|
||||
InChIKey |
BGMZUEKZENQUJY-DACUFJSSSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine 2A receptor | Target Info | Agonist | [525927] | |
5-hydroxytryptamine 2B receptor | Target Info | Agonist | [543921] | ||
5-hydroxytryptamine 2C receptor | Target Info | Agonist | [525477] | ||
WikiPathways | Serotonin Receptor 2 and STAT3 Signaling | ||||
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
SIDS Susceptibility Pathways | |||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR ligand binding | |||||
GPCR downstream signaling | |||||
GPCRs, OtherWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
GPCR downstream signalingWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
References | |||||
Ref 525477 | High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem. 1999 May;72(5):2127-34. | ||||
Ref 525927 | Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem. 2000 Nov 30;43(24):4701-10. | ||||
Ref 543921 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 7). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.